RECRUITING

Preop Laxatives in Robotic Urologic Surgery

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Minimally-invasive surgery, either laparoscopic or robotic, is commonly used in urology. Several urologic procedures including prostatectomy, radical nephrectomy, and partial nephrectomy are now commonly performed robotically. Patients undergoing these procedures often have delayed return of bowel function and persistent gastrointestinal symptoms including nausea/vomiting, abdominal distension, and bloating for several days to weeks after surgery. Postoperative stool softeners and laxatives are routinely used in an effort to minimize these symptoms, with varying degrees of success. The aim of this study will be to evaluate whether the use of a preoperative osmotic laxative will be beneficial in improving recovery of bowel function and alleviating postoperative gastrointestinal complaints in patients undergoing these procedures. Patients will be randomized to either receive or not receive three days of polyethylene glycol (PEG, also known as MiraLAX) on the three days before surgery. Patients in both groups will receive the same postoperative bowel regimen including scheduled PEG both in the hospital and upon discharge until first bowel movement. Patients will be given a questionnaire and diary to record their postoperative gastrointestinal symptoms and time to first bowel movement. These questionnaires and diaries will then be analyzed to determine differences in time to first bowel movement and gastrointestinal complaints during their recovery from surgery.

Official Title

The Use of Preoperative Osmotic Laxatives to Improve Recovery of Bowel Function After Robotic-assisted Urologic Surgery

Quick Facts

Study Start:2023-06-01
Study Completion:2025-03-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05805436

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:30 Years to 100 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. * Patients under 30 years old
  2. * Patients with a contraindication to receiving polyethylene glycol or other forms of laxatives
  3. * People who regularly take Miralax
  4. * Patients undergoing retroperitoneal radical or partial nephrectomy
  5. * Patients with severe ulcerative colitis or Crohn's disease
  6. * Patients with intestinal diversions (colostomy, ileostomy)
  7. * Patients with prior abdominal or pelvic radiation
  8. * Patients who will not follow up with UIHC postoperatively
  9. * Patients who are incarcerated

Contacts and Locations

Study Contact

Chad Tracy, MD
CONTACT
+1 319 335 8056
chad-tracy@uiowa.edu

Study Locations (Sites)

University of Iowa Hospitals & Clinics
Iowa City, Iowa, 52242
United States

Collaborators and Investigators

Sponsor: Chad R. Tracy

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-06-01
Study Completion Date2025-03-03

Study Record Updates

Study Start Date2023-06-01
Study Completion Date2025-03-03

Terms related to this study

Additional Relevant MeSH Terms

  • Prostate Cancer
  • Kidney Cancer
  • Constipation